

6. LITERATURVERZEICHNIS

1. R wert-Huber J, Patel MJ, Forschner T, et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. *Br J Dermatol*. 2007;156 Suppl 3:8-12. Erratum in: *Br J Dermatol* 2007 Aug;157(2):431.
2. Memon AA, Tomenson JA, Bothwell J, Friedmann PS. Prevalence of solar damage and actinic keratosis in a Merseyside population. *Br J Dermatol* 2000;142(6):1154-9.
3. Salasche SJ. Epidemiology of actinic keratoses and squamous cell carcinoma. *J Am Acad Dermatol* 2000;42(1 Pt 2):4-7.
4. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. *J Invest Dermatol* 2000;115(2):273-7
5. Braakhuis BJ, Tabor MP, Kummer JA, Leemans CR, Brakenhoff RH. A genetic explanation of Slaughter's concept of field cancerization: evidence and clinical implications. *Cancer Res* 2003;63(8):1727-30.
6. Moy RL. Clinical presentation of actinic keratoses and squamous cell carcinoma. *J Am Acad Dermatol* 2000;42(1 Pt 2):8-10.
7. Wlaschek M, Tantcheva-Po r I, Naderi L, et al. Solar UV irradiation and dermal photoaging. *J Photochem Photobiol B* 2001;63(1-3):41-51
8. Cockerell CJ. Histopathology of incipient intraepidermal squamous cell carcinoma ("actinic keratosis"). *J Am Acad Dermatol*. 2000;42(1 Pt 2):11-7.
9. Callen JP, Bickers DR, Moy RL. Actinic keratoses. *J Am Acad Dermatol* 1997;36(4):650-3.

10. Meyer T, Arndt R, Christophers E, Nindl I, Stockfleth E. Importance of human papillomaviruses for the development of skin cancer. *Cancer Detect Prev* 2001;25(6):533-47.
11. Harwood CA, Suretheran T, McGregor JM, et al. Human papillomavirus infection and non-melanoma skin cancer in immunosuppressed and immunocompetent individuals. *J Med Virol* 2000;61(3):289-97.
12. Nindl I, Meyer T, Schmook T, et al. Human papillomavirus and overexpression of P16INK4a in nonmelanoma skin cancer. *Dermatol Surg* 2004;30(3):409-14.
13. Harwood CA, Proby CM. Human papillomaviruses and non-melanoma skin cancer. *Curr Opin Infect Dis* 2002;15(2):101-14.
14. Lindelöf B, Sigurgeirsson B, Gäbel H, Stern RS. Incidence of skin cancer in 5356 patients following organ transplantation. *Br J Dermatol* 2000;143(3):513-9.
15. Stockfleth E, Nindl I, Sterry W, Ulrich C, Schmook T, Meyer T. Human papillomaviruses in transplant-associated skin cancers. *Dermatol Surg* 2004;30(4 Pt 2):604-9.
16. Ulrich C, Schmook T, Sachse MM, Sterry W, Stockfleth E. Comparative epidemiology and pathogenic factors for nonmelanoma skin cancer in organ transplant patients. *Dermatol Surg* 2004;30(4 Pt 2):622-7.
17. Glogau RG. The risk of progression to invasive disease. *J Am Acad Dermatol* 2000;42(1 Pt 2):23-4.
18. Stockfleth E, Ulrich C, Meyer T, Christophers E. Epithelial malignancies in organ transplant patients: clinical presentation and new methods of treatment. *Recent Results Cancer Res* 2002;160:251-8.
19. Marks R, Rennie G, Selwood TS. Malignant transformation of solar keratoses to squamous cell carcinoma. *Lancet* 1988;1(8589):795-7.

20. Berking C. Photocarcinogenesis. Molecular mechanisms and preventive strategies. *Hautarzt* 2007;58(5):398-405.
21. Ziegler A, Leffell DJ, Kunala S, et al. Mutation hotspots due to sunlight in the p53 gene of nonmelanoma skin cancers. *Proc Natl Acad Sci U S A* 1993;90(9):4216-20.
22. Kang K, Hammerberg C, Meunier L, Cooper KD. CD11b+ macrophages that infiltrate human epidermis after in vivo ultraviolet exposure potentially produce IL-10 and represent the major secretory source of epidermal IL-10 protein. *J Immunol* 1994;153(11):5256-64.
23. Wilgus TA, Ross MS, Parrett ML, Oberyszyn TM. Topical application of a selective cyclooxygenase inhibitor suppresses UVB mediated cutaneous inflammation. *Prostaglandins Other Lipid Mediat* 2000;62(4):367-84.
24. Seibert K, Zhang Y, Leahy K, et al. Pharmacological and biochemical demonstration of the role of cyclooxygenase 2 in inflammation and pain. *Proc Natl Acad Sci U S A* 1994;91(25):12013-7.
25. Hruza LL, Pentland AP. Mechanisms of UV-induced inflammation. *J Invest Dermatol* 1993;100(1):35S-41S.
26. Afaq F, Adhami VM, Mukhtar H. Photochemoprevention of ultraviolet B signaling and photocarcinogenesis. *Mutat Res.* 2005;571(1-2):153-73.
27. Lee JT Jr, McCubrey JA. The Raf/MEK/ERK signal transduction cascade as a target for chemotherapeutic intervention in leukemia. *Leukemia* 2002;16(4):486-507.
28. Leffell DJ. The scientific basis of skin cancer. *J Am Acad Dermatol* 2000;42(1 Pt 2):18-22.

29. Ziegler A, Jonason AS, Leffell DJ, et al. Sunburn and p53 in the onset of skin cancer. *Nature* 1994;372(6508):773-6.
30. Takahashi T, Nau MM, Chiba I, et al. p53: a frequent target for genetic abnormalities in lung cancer. *Science* 1989;246(4929):491-4.
31. Greenblatt MS, Bennett WP, Hollstein M, Harris CC. Mutations in the p53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. *Cancer Res* 1994;54(18):4855-78.
32. Leonart ME, Vidal F, Gallardo D, et al. New p53 related genes in human tumors: significant downregulation in colon and lung carcinomas. *Oncol Rep* 2006;16(3):603-8.
33. Ulrich M, Forschner T, Röwert-Huber J, et al. Differentiation between actinic keratoses and disseminated superficial actinic porokeratoses with reflectance confocal microscopy. *Br J Dermatol* 2007;156 Suppl 3:47-52.
34. Halliday GM, Bestak R, Yuen KS, Cavanagh LL, Barnetson RS. UVA-induced immunosuppression. *Mutat Res* 1998;422(1):139-45.
35. Porter BO, Malek TR. Prostaglandin E2 inhibits T cell activation-induced apoptosis and Fas-mediated cellular cytotoxicity by blockade of Fas-ligand induction. *Eur J Immunol* 1999;29(7):2360-5.
36. Phipps RP, Stein SH, Roper RL. A new view of prostaglandin E regulation of the immune response. *Immunol Today* 1991;12(10):349-52.
37. Harris SG, Padilla J, Koumas L, Ray D, Phipps RP. Prostaglandins as modulators of immunity. *Trends Immunol* 2002;23(3):144-50.
38. Wang D, Dubois RN. Prostaglandins and cancer. *Gut* 2006;55(1):115-22.

39. Dinehart SM. The treatment of actinic keratoses. *J Am Acad Dermatol* 2000;42(1 Pt 2):25-8.
40. Emmett AJ, Broadbent GD. Shave excision of superficial solar skin lesions. *Plast Reconstr Surg* 1987;80(1):47-54.
41. Braathen LR, Szeimies RM, Basset-Seguín N, et al.; International Society for Photodynamic Therapy in Dermatology. Guidelines on the use of photodynamic therapy for nonmelanoma skin cancer: an international consensus. International Society for Photodynamic Therapy in Dermatology, 2005. *J Am Acad Dermatol* 2007;56(1):125-43.
42. Loven K, Stein L, Furst K, Levy S. Evaluation of the efficacy and tolerability of 0.5% fluorouracil cream and 5% fluorouracil cream applied to each side of the face in patients with actinic keratosis. *Clin Ther* 2002;24(6):990-1000.
43. Johnson R, Stockfleth E. Imiquimod 5% cream for the treatment of cutaneous lesions in immunocompromised patients. *Acta Derm Venereol Suppl (Stockh)* 2003;(214):23-7.
44. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: a novel immune response modifier and new class of drug. *Int J Immunopharmacol* 1999;21(1):1-14.
45. Salasche SJ, Levine N, Morrison L. Cycle therapy of actinic keratoses of the face and scalp with 5% topical imiquimod cream: An open-label trial. *J Am Acad Dermatol* 2002;47(4):571-7.
46. Szeimies RM, Karrer S, Radakovic-Fijan S, et al. Photodynamic therapy using topical methyl 5-aminolevulinate compared with cryotherapy for actinic keratosis: A prospective, randomized study. *J Am Acad Dermatol* 2002;47(2):258-62.

47. Rivers JK, Arlette J, Shear N, Guenther L, Carey W, Poulin Y. Topical treatment of actinic keratoses with 3.0% diclofenac in 2.5% hyaluronan gel. *Br J Dermatol* 2002;146(1):94-100.
48. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronic acid gel for the treatment of actinic keratoses. *Arch Dermatol* 1997;133(10):1239-42.
49. Wolf JE Jr, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. *Int J Dermatol* 2001;40(11):709-13.
50. Gebauer K, Brown P, Varigos G. Topical diclofenac in hyaluronan gel for the treatment of solar keratoses. *Australas J Dermatol* 2003;44(1):40-3.
51. Moore AR, Willoughby DA. Hyaluronan as a drug delivery system for diclofenac: a hypothesis for mode of action. *Int J Tissue React* 1995;17(4):153-6.
52. Karow T, Lang-Roth R. Analgetika. In: *Allgemeine und spezielle Pharmakologie und Toxikologie*. 13. Auflage 2005;592
53. Löffler G. Lipide. In: *Basiswissen Biochemie mit Pathobiochemie*. 5. Auflage. Heidelberg, Deutschland: Springer-Verlag Heidelberg, 2003;185-187
54. Goodwin JS, Ceuppens JL. Effect of nonsteroidal antiinflammatory drugs on immune function. *Semin Arthritis Rheum* 1983;13(1 Suppl 1):134-43.
55. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. *Cell* 1998;93(5):705-16. Erratum in: *Cell* 1998;94(2):following 271.
56. Amano H, Hayashi I, Endo H, et al. Host prostaglandin E(2)-EP3 signaling regulates tumor-associated angiogenesis and tumor growth. *J Exp Med* 2003;197(2):221-32.

57. Wang D, Buchanan FG, Wang H, Dey SK, DuBois RN. Prostaglandin E2 enhances intestinal adenoma growth via activation of the Ras-mitogen-activated protein kinase cascade. *Cancer Res* 2005;65(5):1822-9.
58. Spinella F, Rosanò L, Di Castro V, Natali PG, Bagnato A. Endothelin-1-induced prostaglandin E2-EP2, EP4 signaling regulates vascular endothelial growth factor production and ovarian carcinoma cell invasion. *J Biol Chem* 2004;279(45):46700-5.
59. Sheng H, Shao J, Morrow JD, Beauchamp RD, DuBois RN. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. *Cancer Res* 1998;58(2):362-6.
60. Tsujii M, DuBois RN. Alterations in cellular adhesion and apoptosis in epithelial cells overexpressing prostaglandin endoperoxide synthase 2. *Cell* 1995;83(3):493-501.
61. Maekawa M, Sugano K, Sano H, et al. Increased expression of cyclooxygenase-2 to -1 in human colorectal cancers and adenomas, but not in hyperplastic polyps. *Jpn J Clin Oncol* 1998;28(7):421-6.
62. Gupta S, Srivastava M, Ahmad N, Bostwick DG, Mukhtar H. Over-expression of cyclooxygenase-2 in human prostate adenocarcinoma. *Prostate* 2000;42(1):73-8.
63. Watanabe O, Shimizu T, Imamura H, et al. Expression of cyclooxygenase-2 in malignant and benign breast tumors. *Anticancer Res* 2003;23(4):3215-21.
64. Kokawa A, Kondo H, Gotoda T, et al. Increased expression of cyclooxygenase-2 in human pancreatic neoplasms and potential for chemoprevention by cyclooxygenase inhibitors. *Cancer* 2001;91(2):333-8.

65. Ristimäki A, Nieminen O, Saukkonen K, Hotakainen K, Nordling S, Haglund C. Expression of cyclooxygenase-2 in human transitional cell carcinoma of the urinary bladder. *Am J Pathol* 2001;158(3):849-53.
66. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. *Hum Pathol* 2002;33(2):213-9.
67. Müller-Decker K. Cyclooxygenases in the skin. *J Dtsch Dermatol Ges* 2004;2(8):668-75.
68. Nijsten T, Colpaert CG, Vermeulen PB, Harris AL, Van Marck E, Lambert J. Cyclooxygenase-2 expression and angiogenesis in squamous cell carcinoma of the skin and its precursors: a paired immunohistochemical study of 35 cases. *Br J Dermatol* 2004;151(4):837-45.
69. Guesdon JL, Ternynck T, Avrameas S. The use of avidin-biotin interaction in immunoenzymatic techniques. *J Histochem Cytochem.* 1979;27(8):1131-9.
70. Giorno R. A comparison of two immunoperoxidase staining methods based on the avidin-biotin interaction. *Diagn Immunol* 1984;2(3):161-6.
71. T cell mediated immunity. In: Janeway CA, Travers P, Walport M, Schlomchik MJ, eds. *Immunobiology*. 6th ed. New York, NY USA: Garland Science Publishing 2005:319-66.
72. Vital-Reyes V, Rodríguez-Burford C, Chhieng DC, et al. Celecoxib inhibits cellular growth, decreases Ki-67 expression and modifies apoptosis in ovarian cancer cell lines. *Arch Med Res* 2006;37(6):689-95.
73. Muller WA. Leukocyte-endothelial-cell interactions in leukocyte transmigration and the inflammatory response. *Trends Immunol* 2003;24(6):327-34.

74. Muller WA, Weigl SA, Deng X, Phillips DM. PECAM-1 is required for transendothelial migration of leukocytes. *J Exp Med* 1993;178(2):449-60.
75. Subbaramaiah K, Zakim D, Weksler BB, Dannenberg AJ. Inhibition of cyclooxygenase: a novel approach to cancer prevention. *Proc Soc Exp Biol Med* 1997;216(2):201-10.
76. Black AK, Greaves MW, Hensby CN, Plummer NA. Increased prostaglandins E2 and F2alpha in human skin at 6 and 24 h after ultraviolet B irradiation (290- 320 nm). *Br J Clin Pharmacol* 1978;5(5):431-6.
77. Seo JY, Kim EK, Lee SH, et al. Enhanced expression of cyclooxygenase-2 by UV in aged human skin in vivo. *Mech Ageing Dev* 2003;124(8-9):903-10.
78. Buckman SY, Gresham A, Hale P, et al. COX-2 expression is induced by UVB exposure in human skin: implications for the development of skin cancer. *Carcinogenesis* 1998;19(5):723-9.
79. Wu D, Mura C, Beharka AA, et al. Age-associated increase in PGE2 synthesis and COX activity in murine macrophages is reversed by vitamin E. *Am J Physiol* 1998;275(3 Pt 1):C661-8.
80. Hayek MG, Mura C, Wu D, et al. Enhanced expression of inducible cyclooxygenase with age in murine macrophages. *J Immunol* 1997;159(5):2445-51.
81. Miller RA. The aging immune system: primer and prospectus. *Science* 1996;273(5271):70-4.
82. Vane JR, Botting RM. New insights into the mode of action of anti-inflammatory drugs. *Inflamm Res* 1995;44(1):1-10.
83. Goodwin JS, Ceuppens J. Regulation of the immune response by prostaglandins. *J Clin Immunol* 1983;3(4):295-315.

84. Russell JH, Ley TJ. Lymphocyte-mediated cytotoxicity. *Annu Rev Immunol* 2002;20:323-70
85. Pardo J, Bosque A, Brehm R, et al. Apoptotic pathways are selectively activated by granzyme A and/or granzyme B in CTL-mediated target cell lysis. *J Cell Biol* 2004;167(3):457-68.
86. Kägi D, Ledermann B, Bürki K, et al. Cytotoxicity mediated by T cells and natural killer cells is greatly impaired in perforin-deficient mice. *Nature* 1994;369(6475):31-7.
87. Simon MM, Hausmann M, Tran T, et al. In vitro- and ex vivo-derived cytolytic leukocytes from granzyme A x B double knockout mice are defective in granule-mediated apoptosis but not lysis of target cells. *J Exp Med* 1997;186(10):1781-6.
88. Ortaldo JR, Winkler-Pickett RT, Nagashima K, Yagita H, Okumura K. Direct evidence for release of pore-forming protein during NK cellular lysis. *J Leukoc Biol* 1992;52(5):483-8.
89. Fraser SA, Karimi R, Michalak M, Hudig D. Perforin lytic activity is controlled by calreticulin. *J Immunol* 2000;164(8):4150-5.
90. Vassalli P. The pathophysiology of tumor necrosis factors. *Annu Rev Immunol* 1992;10:411-52.
91. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. *Pharmacol Ther* 2001;92(1):57-70.
92. Einspahr JG, Alberts DS, Warneke JA, et al. Relationship of p53 mutations to epidermal cell proliferation and apoptosis in human UV-induced skin carcinogenesis. *Neoplasia* 1999;1(5):468-75.

93. Nelson MA, Einspahr JG, Alberts DS, et al. Analysis of the p53 gene in human precancerous actinic keratosis lesions and squamous cell cancers. *Cancer Lett* 1994;85(1):23-9.
94. Kubo Y, Urano Y, Yoshimoto K, et al. p53 gene mutations in human skin cancers and precancerous lesions: comparison with immunohistochemical analysis. *J Invest Dermatol* 1994;102(4):440-4.
95. Harris SL, Levine AJ. The p53 pathway: positive and negative feedback loops. *Oncogene* 2005;24(17):2899-908.
96. Eberle J, Fecker LF, Forschner T, Ulrich C, Rówert-Huber J, Stockfleth E. Apoptosis pathways as promising targets for skin cancer therapy. *Br J Dermatol* 2007;156 Suppl 3:18-24.
97. Hofseth LJ, Hussain SP, Harris CC. p53: 25 years after its discovery. *Trends Pharmacol Sci* 2004;25(4):177-81.
98. Sheikh MS, Fornace AJ Jr. Death and decoy receptors and p53-mediated apoptosis. *Leukemia*. 2000;14(8):1509-13.
99. Taguchi M, Watanabe S, Yashima K, Murakami Y, Sekiya T, Ikeda S. Aberrations of the tumor suppressor p53 gene and p53 protein in solar keratosis in human skin. *J Invest Dermatol* 1994;103(4):500-3.
100. Campbell C, Quinn AG, Ro YS, Angus B, Rees JL. p53 mutations are common and early events that precede tumor invasion in squamous cell neoplasia of the skin. *J Invest Dermatol* 1993;100(6):746-8.
101. Kosmadaki MG, Gilchrest BA. The role of telomeres in skin aging/photoaging. *Micron* 2004;35(3):155-9.
102. Gilchrest BA, Bohr VA. Aging processes, DNA damage, and repair. *FASEB J* 1997;11(5):322-30.

103. Garner E, Raj K. Protective mechanisms of p53-p21-pRb proteins against DNA damage-induced cell death. *Cell Cycle* 2008;7(3):277-82.
104. Lodish H, Berk A, Matsudaira P, et al. Regulation of the eukaryotic cell cycle. In: *Molecular cell biology*. 5th ed. New York, NY USA: Freeman 2003:885-890.
105. Miyazaki H, Shiozaki A, Niisato N, et al. Chloride ions control the G1/S cell-cycle checkpoint by regulating the expression of p21 through a p53-independent pathway in human gastric cancer cells. *Biochem Biophys Res Commun* 2008;366(2):506-12.
106. Ohta M, Tateishi K, Kanai F, et al. p53-Independent negative regulation of p21/cyclin-dependent kinase-interacting protein 1 by the sonic hedgehog-glioma-associated oncogene 1 pathway in gastric carcinoma cells. *Cancer Res* 2005;65(23):10822-9.
107. Johnsen JI, Lindskog M, Ponthan F, et al. Cyclooxygenase-2 is expressed in neuroblastoma, and nonsteroidal anti-inflammatory drugs induce apoptosis and inhibit tumor growth in vivo. *Cancer Res* 2004;64(20):7210-5.
108. Johnsen JI, Lindskog M, Ponthan F, et al. NSAIDs in neuroblastoma therapy. *Cancer Lett* 2005;228(1-2):195-201.
109. Inoue A, Muranaka S, Fujita H, Kanno T, Tamai H, Utsumi K. Molecular mechanism of diclofenac-induced apoptosis of promyelocytic leukemia: dependency on reactive oxygen species, Akt, Bid, cytochrome and caspase pathway. *Free Radic Biol Med*. 2004;37(8):1290-9. Erratum in: *Free Radic Biol Med* 2005;38(1):149.
110. Kern MA, Haugg AM, Koch AF, et al. Cyclooxygenase-2 inhibition induces apoptosis signaling via death receptors and mitochondria in hepatocellular carcinoma. *Cancer Res* 2006;66(14):7059-66.

111. Fecker LF, Stockfleth E, Nindl I, Ulrich C, Forschner T, Eberle J. The role of apoptosis in therapy and prophylaxis of epithelial tumours by nonsteroidal anti-inflammatory drugs (NSAIDs). *Br J Dermatol* 2007;156 Suppl 3:25-33.
112. Gerdes J, Lemke H, Baisch H, Wacker HH, Schwab U, Stein H. Cell cycle analysis of a cell proliferation-associated human nuclear antigen defined by the monoclonal antibody Ki-67. *J Immunol* 1984;133(4):1710-5.
113. da Silva TA, Coelho G, Lorenzetti Bocca A, Figueiredo Cavalcante Neto F. Expression of apoptotic, cell proliferation regulatory, and structural proteins in actinic keratosis and their association with dermal elastosis. *J Cutan Pathol* 2007;34(4):315-23.
114. Kreitz S, Fackelmayer FO, Gerdes J, Knippers R. The proliferation-specific human Ki-67 protein is a constituent of compact chromatin. *Exp Cell Res* 2000;261(1):284-92.
115. Brown DC, Cole D, Gatter KC, Mason DY. Carcinoma of the cervix uteri: an assessment of tumour proliferation using the monoclonal antibody Ki67. *Br J Cancer* 1988;57(2):178-81.
116. Gerdes J. Ki-67 and other proliferation markers useful for immunohistological diagnostic and prognostic evaluations in human malignancies. *Semin Cancer Biol* 1990;1(3):199-206.
117. Brown DC, Gatter KC. Monoclonal antibody Ki-67: its use in histopathology. *Histopathology* 1990;17(6):489-503.
118. Jansen RL, Hupperets PS, Arends JW, et al. MIB-1 labelling index is an independent prognostic marker in primary breast cancer. *Br J Cancer* 1998;78(4):460-5.

119. Sittel C, Ruiz S, Volling P, Kvasnicka HM, Jungehülsing M, Eckel HE. Prognostic significance of Ki-67 (MIB1), PCNA and p53 in cancer of the oropharynx and oral cavity. *Oral Oncol* 1999;35(6):583-9.
120. Scholzen T, Gerdes J. The Ki-67 protein: from the known and the unknown. *J Cell Physiol* 2000;182(3):311-22.
121. Qiao L, Shiff SJ, Rigas B. Sulindac sulfide inhibits the proliferation of colon cancer cells: diminished expression of the proliferation markers PCNA and Ki-67. *Cancer Lett* 1997;115(2):229-34.
122. Jones MK, Wang H, Peskar BM, et al. Inhibition of angiogenesis by nonsteroidal anti-inflammatory drugs: insight into mechanisms and implications for cancer growth and ulcer healing. *Nat Med* 1999;5(12):1418-23.
123. Masferrer JL, Leahy KM, Koki AT, et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. *Cancer Res* 2000;60(5):1306-11.